Vivanza Biosciences Limited Stock

Equities

530057

INE984E01035

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:53 2024-04-26 EDT 5-day change 1st Jan Change
8.13 INR +1.25% Intraday chart for Vivanza Biosciences Limited -3.21% -24.51%

Financials

Sales 2022 112M 1.34M 1.84M Sales 2023 182M 2.18M 2.98M Capitalization 752M 9.02M 12.33M
Net income 2022 3M 35.98K 49.19K Net income 2023 5M 59.97K 81.99K EV / Sales 2022 7.22 x
Net Debt 2022 54.52M 654K 894K Net Debt 2023 78.27M 939K 1.28M EV / Sales 2023 4.57 x
P/E ratio 2022
227 x
P/E ratio 2023
126 x
Employees 5
Yield 2022 *
-
Yield 2023
-
Free-Float 39.98%
More Fundamentals * Assessed data
Dynamic Chart
Vivanza Biosciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Vivanza Biosciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Vivanza Biosciences Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Vivanza Biosciences Limited Announces Resignation of Manali S. Patel as Independent Director CI
Vivanza Biosciences Limited Announces Resignation of Girish Bhatt as Managing Director CI
Vivanza Biosciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Vivanza Biosciences Bags Contract to Set Up Pharmaceutical Packaging Facility in Sudan MT
Vivanza Biosciences Limited Announces Receipt of Work Orders Worth Approximately USD 1 Million in Institutional and Industrial Categories CI
Vivanza Biosciences Shelves Planned Preferential Share Allotment MT
Vivanza Biosciences Limited cancelled the transaction announced on July 21, 2022 CI
Vivanza Biosciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Vivanza Biosciences Limited announced a financing transaction CI
Vivanza Biosciences Limited Appoints Avinash G. Bhojwani as Company Secretary and Compliance Officer CI
Vivanza Biosciences Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2022 CI
Vivanza Biosciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
More news
1 day+1.25%
1 week-3.21%
Current month+19.73%
1 month+25.46%
3 months+1.12%
6 months-27.28%
Current year-24.51%
More quotes
1 week
8.00
Extreme 8
8.60
1 month
6.76
Extreme 6.76
9.54
Current year
5.70
Extreme 5.7
11.72
1 year
5.70
Extreme 5.7
16.13
3 years
5.70
Extreme 5.7
21.00
5 years
1.25
Extreme 1.245
21.00
10 years
0.43
Extreme 0.434
21.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 23-04-24
Director of Finance/CFO - 16-06-16
Compliance Officer - 22-05-26
Members of the board TitleAgeSince
Director/Board Member - 19-03-28
Director/Board Member 43 20-10-05
Director/Board Member - 23-04-24
More insiders
Date Price Change Volume
24-04-26 8.13 +1.25% 192,345
24-04-25 8.03 -1.47% 229,301
24-04-24 8.15 -1.45% 239,961
24-04-23 8.27 -0.60% 211,434
24-04-22 8.32 -0.95% 234,446

Delayed Quote Bombay S.E., April 26, 2024 at 06:00 am

More quotes
Vivanza Biosciences Limited is an India-based specialty pharmaceutical company. The Company offers pharmaceutical products and pharma products. The Company is focused on commercializing generic pharmaceuticals, offering patients accessible medicines. The Company operates in only one that is trading of pharmaceutical product. Its products include gloves and surgical. Gloves products include latex examination gloves powdered, latex surgical powdered, latex free examination gloves-vinyl, latex free examination gloves-nitrile and Latex examination gloves-powdered. The Company’s products catalogues include Injectable Products, Vivanza Gloves and Therapeutic Index Injection. The Company offers gloves and surgical products to the industries include chemical, energy, industry, manufacturing and materials.
More about the company
  1. Stock Market
  2. Equities
  3. 530057 Stock